ABBVIE INC. (ABBV)

Price$227.23

Value ScoreD

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-12.58%

Price vs S&P 500 (4W)7.48%

VGM Score45.82

Market Capitalization$401.47B

P/E Ratio (Annual)95.00x

Indicated Dividend Yield (Annual)3.08%

All Metrics

P/CF (Annual)21.10x

Book Value / Share (Quarterly)$0.80

P/TBV (Annual)455.35x

Indicated Dividend (Annual)$6.92

Revenue Growth (3Y)1.75%

Cash Flow / Share (Quarterly)$11.31

Payout Ratio (TTM)325.12%

Price vs S&P 500 (YTD)-12.58%

Gross Margin (TTM)72.03%

Net Profit Margin (TTM)5.79%

EPS (TTM)$2.05

10-Day Avg Trading Volume5.46M

EPS Excl Extra (TTM)$2.05

Revenue Growth (5Y)5.95%

EPS (Annual)$2.38

Dividend / Share (Annual)$6.60

ROI (Annual)6.07%

Gross Margin (Annual)71.62%

Net Profit Margin (5Y Avg)12.88%

Cash / Share (Quarterly)$5.32

P/E Basic Excl Extra (TTM)110.45x

Revenue Growth QoQ (YoY)12.43%

EPS Growth (5Y)-2.88%

P/E Normalized (Annual)95.00x

ROA (Last FY)3.15%

Revenue Growth TTM (YoY)9.50%

EBITD / Share (TTM)$9.08

ROE (5Y Avg)70.88%

Operating Margin (TTM)24.41%

Cash Flow / Share (Annual)$10.08

P/B Ratio282.72x

P/B Ratio (Quarterly)261.01x

Net Income / Employee (Annual)$74,100

EV / Revenue (TTM)7.40x

Net Interest Coverage (TTM)3.46x

ROA (TTM)2.69%

EPS Growth QoQ (YoY)-46.01%

EV / EBITDA (TTM)28.88x

EPS Incl Extra (Annual)$2.38

Current Ratio (Annual)0.67x

Quick Ratio (Quarterly)0.52x

3-Month Avg Trading Volume6.75M

52-Week Price Return20.07%

EV / Free Cash Flow (Annual)26.10x

P/E Incl Extra (TTM)110.45x

Revenue / Employee (TTM)$1,102,100

Tangible BV / Share (Quarterly)$0.14

P/S Ratio (Annual)6.56x

Asset Turnover (Annual)0.46x

52-Week High$244.81

Operating Margin (5Y Avg)25.49%

EPS Excl Extra (Annual)$2.38

CapEx CAGR (5Y)8.75%

26-Week Price Return-1.19%

Quick Ratio (Annual)0.41x

13-Week Price Return-4.76%

Total Debt / Equity (Annual)20.19x

Current Ratio (Quarterly)0.80x

Enterprise Value$464.94B

Revenue / Share Growth (5Y)4.73%

Asset Turnover (TTM)0.46x

Book Value / Share Growth (5Y)-10.06%

Revenue / Employee (Annual)$1,073,000

Inventory Turnover (Annual)3.80x

Pretax Margin (Annual)10.79%

Cash / Share (Annual)$2.97

3-Month Return Std Dev25.47%

Gross Margin (5Y Avg)69.76%

Net Income / Employee (TTM)$63,800

EBITDA CAGR (5Y)5.65%

EBITDA Interim CAGR (5Y)-0.62%

ROE (Last FY)128.66%

Net Interest Coverage (Annual)3.21x

EPS Basic Excl Extra (Annual)$2.38

P/FCF (TTM)20.09x

Receivables Turnover (TTM)5.03x

EV / Free Cash Flow (TTM)23.27x

Total Debt / Equity (Quarterly)49.22x

EPS Incl Extra (TTM)$2.05

Receivables Turnover (Annual)5.20x

ROI (TTM)5.66%

Dividend Growth Rate (5Y)6.76%

P/S Ratio (TTM)6.39x

Pretax Margin (5Y Avg)15.04%

Revenue / Share (Annual)$34.50

Tangible BV / Share (Annual)$0.14

Forward P/E14.49x

Free OCF CAGR (5Y)1.19%

Price vs S&P 500 (52W)-6.97%

P/E Ratio (TTM)110.45x

EPS Growth TTM (YoY)-13.47%

Year-to-Date Return-1.55%

5-Day Price Return3.32%

EPS Normalized (Annual)$2.38

ROA (5Y Avg)5.27%

Net Profit Margin (Annual)6.91%

Month-to-Date Return3.32%

Cash Flow / Share (TTM)$8.66

EBITD / Share (Annual)$8.93

EPS Growth (3Y)-28.99%

Operating Margin (Annual)24.65%

LT Debt / Equity (Annual)18.14x

P/CF (TTM)18.92x

ROI (5Y Avg)8.99%

P/E Excl Extra (TTM)110.45x

LT Debt / Equity (Quarterly)45.44x

EPS Basic Excl Extra (TTM)$2.05

P/TBV (Quarterly)455.35x

Payout Ratio (Annual)275.84%

P/B Ratio (Annual)94.44x

Dividend / Share (TTM)$6.69

Inventory Turnover (TTM)3.67x

Pretax Margin (TTM)9.51%

Book Value / Share (Annual)$1.88

Price vs S&P 500 (13W)-15.27%

Net Margin Growth (5Y)-7.27%

Dividend Yield (TTM)2.94%

Beta0.29x

P/FCF (Annual)22.53x

Revenue / Share (TTM)$35.41

ROE (TTM)95.59%

52-Week Low$181.73

vGradeD

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 262.65est. 2.65

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.86

3.87

3.90

3.95

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ABBVABBVIE INC.	D	C	C	$227.23
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	B	$34.19

About

AbbVie is a diversified pharmaceutical company with core franchises in immunology (Humira, Skyrizi, Rinvoq) and oncology (Imbruvica, Venclexta), complemented by a growing aesthetics business anchored by Botox following the 2020 Allergan acquisition. Recent 2024 acquisitions of Cerevel Therapeutics and Immunogen strengthen its neuroscience and oncology pipelines. The company's multi-therapeutic portfolio leverages established market positions and provides diversified revenue streams.